Introduction 51
In December 2019, Wuhan city (the capital city of Hubei province, China) 52 experienced a major outbreak caused by a novel coronavirus. This outbreak 53 was found to be caused by a novel virus, the severe acute respiratory 54 syndrome coronavirus 2 (SARS-CoV-2). [1] [2] [3] Numerous clinical SARS-Co-2 55 cases have been reported and were distributed among more than half of the 56 countries of the world during a less than 6-month period (data till March 28, 57 2020). [4] [5] [6] [7] The lower respiratory tract is the primary target of the SARS-CoV-2 58 infection. It is noteworthy that adults with coronavirus disease 2019 (COVID-19) 59 often present with a profound decrease in both CD4 + and CD8 + T-cell subsets 60 at the early stage of this disease. 1, 8 Subsequently, patients suffered acute 61 respiratory distress syndrome for about 7-10 days after the onset of COVID-19 62 due to rapid viral replication, a stormy increase of pro-inflammatory cytokines 63 as well as chemokine response, and inflammatory cell infiltrates. 8,9 64 Nevertheless, contrary to the SARS cases in 2003, 10 some SARS-CoV-2 65 infection patients did not have the prodromal symptoms of upper respiratory 66 tract infection (e.g., cough, sore throat, rhinorrhea), viremia-associated 67 laboratory abnormalities (e.g., leukopenia, lymphopenia, anemia, elevation of 68 liver enzymes and lactic dehydrogenase), or initial evidence of diagnostic 69 7 intracellular concentration (>10 μM) of active triphosphate form in peripheral 108 blood mononuclear cells for at least 24 h, 20 supporting its clinical potential in 109 the treatment of human SARS-CoV-2 infection. Additionally, data on the safety 110 of remdesivir in humans are available online. 21 The first COVID-19 patient in 111 the USA was successfully treated with remdesivir for the progression of 112 pneumonia on day 7 of hospitalization in January, 2020. 4 Phase 3 human trials 113 (ClinicalTrials.gov Identifier: NCT04292899 and NCT04292730, for severe and 114 moderate adult SARS-CoV-2 cases, respectively) have been initiated to 115 evaluate its efficacy in patients with SARS-CoV-2 infection since March, 2020. 116 Patients received 200 mg on day 1, followed by 100 mg once daily from day 2. 117
Despite its encouragingly high in vitro potency against SARS-CoV-2 and the 118 clinical success in treatment of COVID-19, 4,18 uncertainties about adverse 119 effects (e.g., nausea, vomiting, rectal hemorrhage, and hepatic toxicity) and 120 clinical efficacy of remdesivir have been reported recently. 22 
121
In a mouse model investigating the pathogenesis of SARS-CoV, 122 prophylactic and early therapeutic post-exposure administration of remdesivir 123 were shown to produce a significant reduction in pulmonary viral load (i.e., >2 124 orders of magnitude on day 2-5 post-infection), mitigate disease progression 125 and prominently improve respiration function. 18 A brief summary of the mechanism of action and targets of potential 265 antimicrobial agents against SARS-CoV-2 is shown in Table 1 . Sequential Organ Failure Assessment score, rise in PaO 2 /FiO 2 , resolution of 313 ARDS (4 patients at 12 days after transfusion), a success of weaning from 314 mechanical ventilation (3 patients within 2 weeks of treatment), and decline in 315 viral loads (became negative within 12 days) and increase in SARS-CoV-2-specific ELISA and neutralizing antibody titers. Of the 5 patients, 3 were 317 discharged from the hospital (lengths of stay: 53, 51, and 55 days), while 2 318 were in stable condition at 37 days after transfusions. 56 The authors concluded 319 that use of convalescent plasma transfusion is beneficial among patients 320 infected with SARS-CoV-2, even though the sample number in this study is 321 small. 56 322 323
Herbal medications 324
Based on the historical records and anecdotal evidence of SARS and H 1 N 1 325 pdm09 prevention, Chinese herbal drugs were also considered as an 326 alternative approach for prevention of COVID-19 in high-risk populations. 
